Parecoxib guide history

Document Title

Guidelines for the use of subcutaneous parecoxib in palliative patients with cancer pain

Document Date

March 2024

Document Purpose and Intended Audience

This guideline provides information about the use of subcutaneous parecoxib in palliative care patients for cancer pain


Dr Nadia Khan

Consultation Process

Discussed and ratified at SPAGG


This will be audited and reviewed every 3 years

Review Date

(must be within three years)

MArch 2027

Approval Signatures:

SPAGG chair

Dr Jon Tomas

SPAGG secretary

Dr Alice Martin

Date Approved by SPAGG: March 2024

Date submitted to Area Prescribing Committee: N/A

Version History

Version 1


March 2021

Summary of change/ process


Version 2


March 2024

Summary of change/ process

Reviewed and update by M Aslett

Disclaimer (SPAGG - Rewrite)

This Guide is intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.

Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.

While WMPCPS takes every care to compile accurate information , we cannot guarantee its correctness and completeness and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.